Nine years ago, 66-year-old lady was diagnosed late Secretary of lung cancer , when doctors told her only live for a few months, suffered a blow to despair; nine years later, 75-year-old lady is still Secretary of patients with advanced lung cancer, but she has lived After nine years of normal everyday life, but also to care for a sick wife. Cancer for her, just as diabetes and hypertension, as managed instill obedience.
In our clinical practice, not a rare case, Ms. Secretary, with the deepening of individualized comprehensive treatment of lung cancer research, such a miracle has been more and more, even should no longer be called a miracle. - As long as the appropriate treatment, patients with advanced lung cancer can bring long-term survival, and can work and live.
Typical case: with survival in patients with advanced lung cancer more than nine years
In 2005, Secretary Ms. Zibo, because of cough, hemoptysis , was diagnosed with advanced lung cancer, because the disease is still rapid progress, the doctor told her only live for a few months. June 2005, the Secretary Ms. removed to the hospital, taking into account the already advanced inoperable disease and for chemotherapy and radiotherapy are not sensitive to the decision to the Secretary Ms. targeted therapy that is slow release libraries therapy, is through direct puncture embedded in the drug within the tumor, slow release directly kill the tumor. Today, the company has brought Ms. survival more than seven years, the disease has been well under control, are completely normal life.
In the past: the existence of "trial and error mode", effective in only three percent
Lung cancer is a very high death rate of malignant disease, is the world's number one cancer killer. 2005 statistics, the annual number of deaths from lung cancer more than 60 people, including non -small cell lung cancer accounts for about 80%. Now this figure will be higher.
At the same time, because 80% of lung cancer patients for treatment at advanced stage, lost the opportunity to surgery, the patient can even surgery are prone to relapse and metastasis, put together, the efficacy of chemotherapy is not obvious, therefore, the patient's survival not ideal, many patients once diagnosed, it has entered the life of "Countdown."
In advanced non-small cell lung cancer line chemotherapy, even if the two drugs containing platinum standard program, the actual efficiency is only about 30%, meaning that nearly 70% of patients are not markedly. In the treatment of lung cancer, in the past there has been a "trial and error mode", which in the case of tumor genotyping unclear, for advanced lung cancer, invariably given chemotherapy, the use of a drug can only try after another ineffective a drug until the trial on the cancer cells can produce a kind of inhibition of the drug. This model is not only poor efficacy, adverse reactions, but also result in excessive waste of medical resources.
Future: Join a therapeutic vaccine for advanced lung cancer is expected to get better treatment
Dendritic cell vaccine (referred to as DC vaccine) is a therapeutic vaccine, in September 2010, the U.S. Food and Drug Administration (FDA) approved the first treatment for metastatic prostate cancer DC vaccine. FDA approval can be demanding clinical applications for advanced tumors, indicating that DC vaccine really promising. In clinical treatment, we also found that for patients with advanced lung cancer, targeted therapy and immunotherapy cells have synergistic effect, therefore, on the basis of targeted therapy, combined therapeutic vaccine would be a good mode of treatment, if successful Patients will be able to rely on their own entirely immune to cure the disease. Currently, the library sustained release therapy has been introduced immunotherapy successfully targeted therapy and immunotherapy combines advanced lung cancer is expected to get better treatment.